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Meningiomas account for one-third of all adult central nervous system tumours and are divided into three WHO grades. In
contrast to the relatively well characterized genetic alterations, our current understanding of epigenetic modifications involved
in the meningioma-genesis and progression is rather incomplete. Contrary to genetic alterations, epigenetic changes do not alter
the primary DNA sequence and their reversible nature serves as an excellent basis for prevention and development of novel
personalised tumour therapies. Indeed, growing body of evidence suggests that disturbed epigenetic regulation plays a key role
in the pathogenesis of meningiomas. Altered DNA methylation, microRNA expression, histone, and chromatin modifications are
frequently noted in meningiomas bearing prognostic and therapeutic relevance. In this review we provide an overview on recently
identified epigenetic alterations in meningiomas and discuss their role in tumour initiation, progression, and recurrence.
1. Introduction
Meningiomas originate from arachnoidal cap cells of the
leptomeninges and account for around 30% of all central
nervous system (CNS) tumours in adults. Their incidence
increases with age with a female :male ratio of 2 : 1. Fur-
thermore, autopsy and imaging studies indicate that the
prevalence of subclinical meningiomas is roughly 3% in the
population [1]. According to the World Health Organization
(WHO) meningiomas can be divided into three histological
grades: benign (grade 1), atypical (grade 2), and anaplastic
meningiomas (grade 3). Besides this classification several
other subtypes and variants exist (Table 1) [2, 3]. Although,
90% of meningiomas are typically benign slow-growing
tumours, grade 2 and 3 tumours exhibit aggressive clinical
phenotype with an increased risk of recurrence and invasive
growth pattern [4]. The main histopathological character-
istics of the different grades and subtypes were thoroughly
reviewed by Riemenschneider et al. [5].
However, most meningiomas are sporadic; they are rarely
associated with familial tumour syndromes such as Li-
Fraumeni, Turcot, Gardener, von Hippel-Lindau, Cowden,
Gorlin, and multiple endocrine neoplasia type I (MEN1) [6].
The aetiology of meningiomas is still unclear; ionizing
radiation, head trauma, hormone-replacement therapy, and
advanced age are the established risk factors though [7].
While the cytogenetic landscape of tumours is well known,
the molecular mechanisms underlying progression and
recurrence are not well defined. Cytogenetic alterations of
chromosome 22 and NF2 gene are characteristic genetic
alterations in early tumorigenesis and are frequently noted in
higher grade tumours. In contrast to benign meningiomas,
grade 2 and 3 tumours display more complex cytogenetic and
molecular background with activation of oncogenes, inacti-
vation of tumour suppressor genes, and alterations in other
genes involved in several cellular pathways (Figure 1) [8].
Despite the identification ofmany potential molecular targets
current treatment strategies are still limited to conventional
forms of tumour therapy [9].
During the last decade, disruption of normal epigenetic
regulation has been recognized as a novel hallmark of cancer
[10]. Deeper understanding of epigenetic modifications in
meningiomasmay increase our knowledge regarding tumori-
genesis, progression, and recurrence. The goal of our review
is to provide an overview of advances in the field of menin-
gioma epigenetics with focus on possible biomarkers which
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Figure 1: Characteristic cytogenetic and molecular alterations of the different WHO grades of meningiomas.
Table 1: The histological subtypes of meningiomas.
Histological subtypes
Benign meningioma
(WHO grade 1)
Meningothelial, fibrous or fibroblastic,
transitional or mixed, psammomatous,
angiomatous, microcystic, secretory,
lymphoplasmacyte-rich, and
metaplastic meningioma
Atypical meningioma
(WHO grade 2)
Chordoid, clear cell, atypical, and brain
invasive meningioma
Anaplastic meningioma
(WHO grade 3)
Papillary, rhabdoid, and anaplastic or
malignant meningioma
may open the door to novel and more effective molecular
diagnosis and therapies.
2. Epigenetic Profile of Meningiomas
In the past cancer was viewed as a disease initiated by the
accumulation of genetic alterations causing neoplastic trans-
formation in the respective cell type of origin. However,
in the new millennium, it has become evident that also
epigenetic regulation plays a prominent role in tumorige-
nesis. In principle, epigenetic modifications are heritable
changes that influence gene expression without altering the
primary sequence of DNA [11]. Besides cancer, disruption
of the normal epigenetic regulation may also contribute to
the pathogenesis of inflammatory, autoimmune, metabolic,
neurological, and blood disorders [12]. Since the basics of
epigenetics in cancer had been established it has become
one of the most promising research fields of neurooncol-
ogy which may reveal potential targets for drug develop-
ment and therapy [13]. However, the epigenetic landscape
of meningiomas remains still incomplete with altered DNA
methylation, aberrant microRNA expression, and mutant
epigenetic modifiers (EMGs) involved in histone and chro-
matin modifications being potential epigenetic markers of
progression and recurrence (Table 2).
2.1. Aberrant DNA Methylation in Meningiomas. Altered
DNA methylation was the first epigenetic mark shown to be
associated with cancer caused by both global DNA hypo-
methylation and/or promoter hypermethylation of certain
genes. De novo methylation of DNA is catalysed by the
enzymes DNMT3A and DNMT3B whereas maintenance of
methylation is mediated by DNMT1 (Figure 2) [14, 15].
Intriguingly, NF2 (neurofibromatosis-2; a gene known
to be frequently involved in development of meningiomas)
promotermethylation does not play a key role inmeningioma
development [16]. Nevertheless, emerging evidence supports
the involvement of DNA methylation in meningioma pro-
gression [13]. In contrast toNF2, the promotermethylation of
tissue inhibitor of metalloproteinase 3 (TIMP3), located quite
close to the NF2 gene, is inactivated in meningiomas [17].
Hypermethylation of TIMP3 is present in 67% of anaplastic
meningiomas, but only in 22% of atypical and 17% of benign
meningiomas. Thus, inactivation of TIMP3 by methylation
may be involved in meningioma progression and can be a
potential marker of an aggressive, high-grade meningioma
phenotype [18]. Similar to TIMP3, repression of HOXA7,
HOXA9, and HOXA10 in meningioma is also associated
with clinically aggressive behaviour. DNA methylation levels
of HOXA7, HOXA9, and HOXA10 were reported to be
significantly higher in atypical and anaplastic meningiomas
than in the benign form [19]. The methylation status of
these three genes was lower in newly diagnosed grade 1
meningiomas in contrast to their recurrent counterpart and
multiplex meningiomas presented with significantly higher
HOXA10 methylation as compared to solitary meningiomas
[20]. Promoter methylation of RASSF1A, TP73, and NDRG2
is more frequent in higher grade tumours than in benign
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Table 2: Epigenetic changes and their supposed role in meningiomas.
Epigenetic
alterations Affected genes
Distribution between
WHO grades Possible effects in meningioma
Promoter
methylation
TIMP3 Grades 1 < 2 < 3 Associated with tumour progression and aggressiveness parameters
HOXA7, HOXA9,
and HOXA10 Grades 1 < 2 < 3 Associated with tumour progression and aggressiveness parameters
RASSF1A Grades 1 < 2 < 3 Associated with the malignant transformation of a meningioma
TP73 Grades 1 < 2 < 3 Associated with the malignant transformation of a meningioma
NDRG2 Grades 1 < 2 < 3 Associated with malignant progression and predisposition to recurrence
MAL2 Grade 1 Unknown
IGF2BP1 Grade 2 Increases the malignant potential of tumours
PDCD1 Grade 2 Increases the malignant potential of tumours
Disturbed
chromatin
regulation
KDM5C Grades 1 and 3 Disturbed chromatin regulation
KDM6A Grade 2 Disturbed chromatin regulation
SMARCB1 Grade 1 Abnormal chromatin remodelling
Abnormal
microRNAs
expression
miR-29c-3p Grades 1 > 2 > 3 Associated with advanced clinical stages
miR-219-5p Grades 1 > 2 > 3 Associated with advanced clinical stages
miR-190a Grades 1 < 2 < 3 Associated with advanced clinical stages
miR-200a Unknown Functions as a multifunctional tumour suppressor miRNA
miR-145 Grades 1 > 2; 3 Has an important antimigratory and antiproliferative function
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Figure 2: Schematic representation of unmethylated (a) and methylated (b) genes. The most CpG islands in the promoter region of normal
genes are unmethylated (a) [11]. DNA methylation refers to the addition of a methyl (CH
3
) group to the fifth carbon atom of the cytosine
residues resulting in the formation of 5-methylcytosine (b). The process is mediated by DNA methyltransferase enzymes. DNA methylation
occurs mainly at cytosine-guanosine dinucleotides (CpGs) which are concentrated in promoter CpG islands. CpG islands are short DNA
sequences (<200 bp) with greater than 50% GC content. Methylation of CpGs in promoter regions plays an important role in both chromatin
structure control and gene expression [14].
meningioma [21, 22]. Repressed O6-methylguanine-DNA
methyltransferase (MGMT) by promoter methylation is a
prognostic biomarker in glioblastoma (GBM) [23]. The
alkylating chemotherapeutic agent temozolomide (TMZ)
increases the overall survival in GBM patients where the
MGMT gene is methylated [24]. Unlike the vast majority
of gliomas, testing the MGMT methylation status is not es-
sential because the gene is unmethylated in the majority of
meningiomas [25]. On the other hand, Larijani et al. found an
increased but statistically not significantMGMTmethylation
with higher tumour grade, it wasmore frequent inmales [26].
High-throughput techniques have made the genome-
wide methylation analysis of human tumours including
meningiomas possible. Evidence suggests that anaplastic
meningioma could be distinguished fromatypical and benign
tumours according to DNA methylation patterns [19]. In
addition, unlike in benign meningiomas, grade 2 and 3
tumours demonstrate increased global DNA hypomethyla-
tion. Interestingly, the majority of hypermethylated genes are
suppressed in all tumours, but MAL2 is highly expressed
in grade 1 and silenced in grade 3 meningiomas [27].
Another study identified nine differentially methylated genes
by whole genomemethylation analysis of benign and atypical
meningiomas. The largest difference in methylation status
was observed in IGF2BP1 and PDCD1 [28]. IGF2BP1 encodes
the IGF2mRNAbinding protein 1 (IGF2BP1) whichmediates
the cytoplasmic fate of specific target mRNAs including
ACTB and CD44. IGF2BP1 is a potent oncogenic factor
that regulates the adhesion, migration, and invasiveness of
tumour cells by modulating intracellular signalling [29].
Using genome-wide methylation analysis, grade 1 and 2
meningiomas can be divided into three subgroups. Based
on this result, a simplified scoring system with five hyper-
methylated genes (HOXA6, HOXA9, PENK, UPK3A, and
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IGF2BP1) was proposed. This classification correlates well
with recurrence and progression but there was no association
with WHO histological or Simpson neurosurgical grades
[30].
2.2. Mutations Related to Histone Modifications. Histone
modifications are disturbed in many diseases including can-
cer. Histone octamer cores are formed by two copies of
each histone protein (H2A, H2B, H3, and H4) and one H1
linker histone [31, 32]. Besides DNA condensation, histone
proteins are also involved in regulation of gene expres-
sion by posttranslational modifications which mainly occur
along their N-terminal tail. Histones can be modified by
acetylation, methylation, phosphorylation, sumoylation, and
ubiquitination. These modifications can result in an open
(euchromatin) or closed (heterochromatin) state of the chro-
matin [31, 33]. Hence, methylated H3K9, H3K27, and H4K20
can result in a closed chromatin conformation, while open
chromatin structure can be caused by methylated H3K4,
H3K36, and H3K79 [34].
Not much is known about the precise role of these
modifications in the initiation and progression of cancer.
Histone modification pattern such as histone H3 lysine 9
trimethylation (H3K9me3), which has a prognostic relevance
in glioblastoma, has not been detected in meningiomas
yet [35]. On the other hand, current genome-wide studies
reported mutations of epigenetic modifier genes encod-
ing proteins that regulate the chromatin structure of cells.
Among the affected EMGs KDM5C and KDM6A are histone
demethylases, while SMARCB1 and SMARCE1 are members
of the SWI/SNF chromatin-remodelling complex [36, 37].
2.3. Role of MicroRNAs in Meningiomas. MicroRNAs (miR-
NAs) are single-stranded noncoding RNAs, composed of 19
to 24 nucleotides, and play regulatory roles in important
biological processes, such as cell cycle, proliferation, differ-
entiation, migration, and apoptosis [38]. They cause post-
translational gene expression silencing by binding to com-
plementary sites on their target mRNAs and initiate either
degradation or inhibition of translation. Dysregulated miR-
NAs expression was described in a number of human dis-
eases, including cardiovascular, autoimmune, inflammatory,
neurodevelopmental diseases and cancer [39, 40]. Altered
miRNA expression is associated with both genetic and epi-
genetic mechanisms. miRNAs usually have reduced levels in
tumour cells and probably function as oncogenes or as
tumour suppressors [41]. In cancer, several miRNAs correlate
well with clinicopathological features, such as metastasis,
recurrence, and length of survival [42].
MicroRNA expression profiling ofmeningiomas revealed
downregulation of miR-29c-3p and miR-219-5p, which were
associated with advanced clinical stages. High expression of
miR-190a and low expression of miR-29c-3p and miR-219-
5p are correlated with significantly higher recurrence rates
in meningioma patients. Importantly, miR-190a expression
level is a prognostic predictor of postsurgical outcomes
[43]. The mRNA of 𝛽-catenin is a target for miR-200a;
consequently 𝛽-catenin translation and Wnt signalling are
suppressed by overexpressed miR-200a [44], and miR-200a
may act as a multifunctional tumour suppressor miRNA. A
direct correlation was found between the downregulation
of miR-200a and the upregulation of 𝛽-catenin in menin-
giomas. Reduced miR-200a causes decreased expression of
the ZEB1 and SIP1 transcription factors resulting in the
downregulation of E-cadherin [45]. Moreover, it provokes an
increased 𝛽-catenin and cyclin D1 expression and activates
the Wnt signalling pathway in meningiomas [46]. miR-145
may have an important antimigratory and antiproliferative
function in cancer [47]. Contrary to grade 1 meningiomas,
significantly decreased miR-145 levels were detected in grade
2 and 3 tumours. Increased levels of miR-145 may result in
downregulated collagen type V alpha (COL5A1) expression.
Accordingly, COL5A1 expression is upregulated in atypical
and anaplastic meningiomas [48].
3. Conclusion
In the past decade it has become evident that epigenetic
factors are involved in tumour pathogenesis. Contrary to
genetic alterations, epigenetic changes do not alter the pri-
mary DNA sequence and their reversible nature serves as
an excellent basis for prevention and development of novel
and personalised cancer therapies. Similar to other tumours,
disturbed epigenetic regulation plays a key role in the
pathogenesis of meningiomas. DNAmethylation, microRNA
expression, histone, and chromatin modifications can be
altered in meningiomas with a prognostic relevance and may
become a potential therapeutic target in the future.
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